Vaccine value profile for Neisseria gonorrhoeae

作者：Yiming Lyu, Annabelle Choong, Eric P. F. Chow, Kate L. Seib, Helen Marshall, Magnus Unemo, Alex de Voux, Bing Wang, Angélica Espinosa Miranda, Sami L. Gottlieb, Maeve B. Mello, Teodora Wi, Rachel Baggaley, Caroline Marshall, Laith J. Abu‐Raddad, Winston E. Abara, Xiang‐Sheng Chen, Jason J. Ong · 发表于：Vaccine · 年份：2023 · DOI：10.1016/j.vaccine.2023.01.053 · 被引用次数：32 · 研究领域：Reproductive tract infections research、Bacterial Infections and Vaccines、Vaccine Coverage and Hesitancy

Neisseria gonorrhoeae infection (gonorrhoea) is a global public health challenge, causing substantial sexual and reproductive health consequences, such as infertility, pregnancy complications and increased acquisition or transmission of HIV. There is an urgency to controlling gonorrhoea because of increasing antimicrobial resistance to ceftriaxone, the last remaining treatment option, and the potential for gonorrhoea to become untreatable. No licensed gonococcal vaccine is available. Mounting observational evidence suggests that N. meningitidis serogroup B outer membrane vesicle-based vaccines may induce cross-protection against N. gonorrhoeae (estimated 30%-40% effectiveness using the 4CMenB vaccine). Clinical trials to determine the efficacy of the 4CMenB vaccine against N. gonorrhoeae are underway, as are Phase 1/2 studies of a new gonococcal-specific vaccine candidate. Ultimately, a gonococcal vaccine must be accessible, affordable and equitably dispensed, given that those most affected by gonorrhoea are also those who may be most disadvantaged in our societies, and most cases are in less-resourced settings. This vaccine value profile (VVP) provides a high level, holistic assessment of the current data to inform the potential public health, economic and societal value of pipeline vaccines. This was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships and multi-lateral organizations. All contributors ha...